|Friday, 14 October 2011 00:00|
Earlier in the week, there was a substantial insider buy placed by Mark N. Lampert of the BioTechnology Value Fund, LP and his buying activity put shares on the higher end of the tight trading range that had been in play for NBIX shares since August.
Shares of NBIX closed at $6.42+0.39 (up 6.47%) on Thursday after we told our premium subscribers that continued volume might push the stock higher. As it stands, shares broke out of their trading range after closing above the 50-day moving average on Wednesday. In addtion, Roberto Pedone of StockPickr published his own article on Thursday afternoon pointing to the potential upside for NBIX at these levels. From a technical analysis standpoint, the stock is not set to run into considerable resistance until the $7.85 mark.
Neurocrine Biosciences Inc is focused on the development and clomid commercialization of innovative pharmaceutical products to treat unmet medical needs. The firm's research and development efforts are focused on neurological and endocrine diseases and disorders. Its product candidates address some of the largest pharmaceutical markets including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasis (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders.
On Tuesday Oct 4th, Neurocrine announced that it had received a $20 million milestone payment from development partner Abbott Laboratories for the gynecological drug candidate elagolix. The companies are developing elagolix as a treatment for pain associated with endometriosis, a condition in which a tissue similar to the uterine lining is found outside of the uterus, such as on the ovaries. The condition can cause pelvic pain and infertility. Neurocrine said it has received $30 million in milestone payments in the third quarter.
If you're the type who likes to follow insider money into trades, then you should know that Biotechnology Value Fund Partners LP (BVF Partners LP) is a private investment partnership founded in 1993 by President and Portfolio Manager Mark Lampert. Lampert was once Vice President at Oppenheimer & Co. where he created various biotechnology investment vehicles. Mr. Lampert also founded Biotechnology Royalty Corp, which pooled university patent royalties, prior to joining Oppenheimer. The firm manages the Biotechnology Value Fund which pursues activist investment strategies in biotechnology equities.